Long Term Follow-up Study for Subjects Administered CLBR001
Launched by CALIBR, A DIVISION OF SCRIPPS RESEARCH · Mar 12, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is a long-term follow-up study designed to keep track of patients who have received a treatment called CLBR001. CLBR001 is a type of gene therapy that uses special technology to help the body fight certain conditions. The main goal of this study is to monitor participants for up to 15 years after they received the treatment to see if there are any delayed side effects or problems that may come up later on.
To participate in this study, individuals must be between the ages of 65 and 74 and have received at least one dose of the CLBR001 treatment. There are no specific exclusions for this trial, which means most people who qualify can join. Participants can expect to be monitored over the years for their health and any effects related to the treatment. This study is important because it helps researchers understand the long-term safety and effectiveness of gene therapies like CLBR001.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects who received at least one CLBR001 cell dose.
- Exclusion Criteria:
- • None
About Calibr, A Division Of Scripps Research
Calibr, a division of Scripps Research, is a pioneering biotechnology organization dedicated to advancing the discovery and development of transformative therapies. Leveraging cutting-edge science and innovative technologies, Calibr focuses on translating high-impact research into clinically viable solutions for unmet medical needs. The organization collaborates with academic institutions, industry partners, and clinical investigators to accelerate the progress of novel treatments, particularly in the fields of immunology, oncology, and regenerative medicine. With a commitment to excellence and a patient-centered approach, Calibr aims to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Chief Medical Officer
Study Director
Calibr-Skaggs Institute for Innovative Medicines
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported